Neurology 1999;53:517
© 1999 American Academy of Neurology
Articles
APOE genotype, plasma lipids, lipoproteins, and AD in community elderly
Stavra N. Romas, MD,
Ming-Xin Tang, PhD,
Lars Berglund, MD and
Richard Mayeux, MD, MSc
From the Taub Center for Alzheimer’s Disease Research, the Gertrude H. Sergievsky Center (Drs. Romas, Tang, and Mayeux), the Departments of Medicine (Dr. Berglund), Neurology (Drs. Romas and Mayeux), and Psychiatry (Dr. Mayeux), and the Divisions of Epidemiology (Dr. Mayeux) and Biostatistics (Dr. Tang), School of Public Health, Columbia University, New York, NY.
Address correspondence and reprint requests to Dr. Richard Mayeux, Gertrude H. Sergievsky Center, 630 West 168th Street, Columbia University, New York, NY 10032.
BACKGROUND: Genetic variation at the APOE locus has a major influence on both plasma lipid levels and the risk of AD. The relationship between APOE genotype and plasma lipids may influence the risk of AD.
OBJECTIVE: In a community-based study of white, African American, and Caribbean Hispanic elderly in New York City, we investigated the relationship between plasma lipids and AD as well as the possible influence of APOE genotype on this relationship.
METHODS: Total plasma cholesterol (TC), low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglyceride levels were investigated in a cross-sectional study of nondemented elderly and patients with AD and in a prospective study of incident AD. Analyses included APOE genotype, gender, ethnicity, body mass index, and other potential confounders such as a history of hypertension, smoking, aspirin use, previous stroke, or ischemic heart disease.
RESULTS: Compared with nondemented elderly, decreased TC level had a weak but significant inverse association with incident AD, independent of APOE genotype. No other lipoprotein fragment was associated with either prevalent or incident AD.
CONCLUSION: Our results suggest that no consistent relationship exists between APOE genotype, plasma lipoproteins, and AD.
This article has been cited by other articles:
|
|
|
|
 
E. van Exel, P. Eikelenboom, H. Comijs, M. Frolich, J. H. Smit, M. L. Stek, P. Scheltens, J. E. Eefsting, and R. G. J. Westendorp
Vascular Factors and Markers of Inflammation in Offspring With a Parental History of Late-Onset Alzheimer Disease
Arch Gen Psychiatry,
November 1, 2009;
66(11):
1263 - 1270.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P. Kennelly, B. A. Lawlor, and R. A. Kenny
Review: Blood pressure and dementia -- a comprehensive review
Therapeutic Advances in Neurological Disorders,
July 1, 2009;
2(4):
241 - 260.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Singh-Manoux, D. Gimeno, M. Kivimaki, E. Brunner, and M. G. Marmot
Low HDL Cholesterol Is a Risk Factor for Deficit and Decline in Memory in Midlife: The Whitehall II Study
Arterioscler Thromb Vasc Biol,
August 1, 2008;
28(8):
1556 - 1562.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Scarmeas
Invited Commentary: Lipoproteins and Dementia--Is It the Apolipoprotein A-I?
Am. J. Epidemiol.,
May 1, 2007;
165(9):
993 - 997.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Solomon, I. Kareholt, T. Ngandu, B. Winblad, A. Nissinen, J. Tuomilehto, H. Soininen, and M. Kivipelto
Serum cholesterol changes after midlife and late-life cognition: Twenty-one-year follow-up study
Neurology,
March 6, 2007;
68(10):
751 - 756.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Jasinska-Myga, G. Opala, C. G. Goetz, J. Tustanowski, S. Ochudlo, A. Gorzkowska, and J. Tyrpa
Apolipoprotein E Gene Polymorphism, Total Plasma Cholesterol Level, and Parkinson Disease Dementia
Arch Neurol,
February 1, 2007;
64(2):
261 - 265.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Hall, J. Murrell, A. Ogunniyi, M. Deeg, O. Baiyewu, S. Gao, O. Gureje, J. Dickens, R. Evans, V. Smith-Gamble, et al.
Cholesterol, APOE genotype, and Alzheimer disease: An epidemiologic study of Nigerian Yoruba
Neurology,
January 24, 2006;
66(2):
223 - 227.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Li, J. B. Shofer, W. A. Kukull, E. R. Peskind, D. W. Tsuang, J.C.S. Breitner, W. McCormick, J. D. Bowen, L. Teri, G. D. Schellenberg, et al.
Serum cholesterol and risk of Alzheimer disease: A community-based cohort study
Neurology,
October 11, 2005;
65(7):
1045 - 1050.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. M. Mielke, P. P. Zandi, M. Sjogren, D. Gustafson, S. Ostling, B. Steen, and I. Skoog
High total cholesterol levels in late life associated with a reduced risk of dementia
Neurology,
May 24, 2005;
64(10):
1689 - 1695.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Dufouil, F. Richard, N. Fievet, J. F. Dartigues, K. Ritchie, C. Tzourio, P. Amouyel, and A. Alperovitch
APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: The Three-City Study
Neurology,
May 10, 2005;
64(9):
1531 - 1538.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Solfrizzi, F. Panza, A. M. Colacicco, A. D'Introno, C. Capurso, F. Torres, F. Grigoletto, S. Maggi, A. Del Parigi, E. M. Reiman, et al.
Vascular risk factors, incidence of MCI, and rates of progression to dementia
Neurology,
November 23, 2004;
63(10):
1882 - 1891.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Fagan, E. Christopher, J. W. Taylor, M. Parsadanian, M. Spinner, M. Watson, J. D. Fryer, S. Wahrle, K. R. Bales, S. M. Paul, et al.
ApoAI Deficiency Results in Marked Reductions in Plasma Cholesterol But No Alterations in Amyloid-{beta} Pathology in a Mouse Model of Alzheimer's Disease-Like Cerebral Amyloidosis
Am. J. Pathol.,
October 1, 2004;
165(4):
1413 - 1422.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Evans, S. Hui, A. Perkins, D. K. Lahiri, J. Poirier, and M. R. Farlow
Cholesterol and APOE genotype interact to influence Alzheimer disease progression
Neurology,
May 25, 2004;
62(10):
1869 - 1871.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Mayeux, L. S. Honig, M.-X. Tang, J. Manly, Y. Stern, N. Schupf, and P. D. Mehta
Plasma A{beta}40 and A{beta}42 and Alzheimer's disease: Relation to age, mortality, and risk
Neurology,
November 11, 2003;
61(9):
1185 - 1190.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.A. Pappolla, T.K. Bryant-Thomas, D. Herbert, J. Pacheco, M. Fabra Garcia, M. Manjon, X. Girones, T.L. Henry, E. Matsubara, D. Zambon, et al.
Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology
Neurology,
July 22, 2003;
61(2):
199 - 205.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. S. Tan, S. Seshadri, A. Beiser, P. W. F. Wilson, D. P. Kiel, M. Tocco, R. B. D'Agostino, and P. A. Wolf
Plasma Total Cholesterol Level as a Risk Factor for Alzheimer Disease: The Framingham Study
Arch Intern Med,
May 12, 2003;
163(9):
1053 - 1057.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Engelhart, M. I. Geerlings, A. Ruitenberg, J. C. van Swieten, A. Hofman, J. C.M. Witteman, and M. M.B. Breteler
Diet and risk of dementia: Does fat matter?: The Rotterdam Study
Neurology,
December 24, 2002;
59(12):
1915 - 1921.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Kivipelto, E.-L. Helkala, M. P. Laakso, T. Hanninen, M. Hallikainen, K. Alhainen, S. Iivonen, A. Mannermaa, J. Tuomilehto, A. Nissinen, et al.
Apolipoprotein E {epsilon}4 Allele, Elevated Midlife Total Cholesterol Level, and High Midlife Systolic Blood Pressure Are Independent Risk Factors for Late-Life Alzheimer Disease
Ann Intern Med,
August 6, 2002;
137(3):
149 - 155.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Hajjar, J. Schumpert, V. Hirth, D. Wieland, and G. P. Eleazer
The Impact of the Use of Statins on the Prevalence of Dementia and the Progression of Cognitive Impairment
J Gerontol A Biol Sci Med Sci,
July 1, 2002;
57(7):
M414 - M418.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V Solfrizzi, F Panza, A D'Introno, A M Colacicco, C Capurso, A M Basile, and A Capurso
Lipoprotein(a), apolipoprotein E genotype, and risk of Alzheimer's disease
J. Neurol. Neurosurg. Psychiatry,
June 1, 2002;
72(6):
732 - 736.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Yaffe, E. Barrett-Connor, F. Lin, and D. Grady
Serum Lipoprotein Levels, Statin Use, and Cognitive Function in Older Women
Arch Neurol,
March 1, 2002;
59(3):
378 - 384.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Rockwood, S. Kirkland, D. B. Hogan, C. MacKnight, H. Merry, R. Verreault, C. Wolfson, and I. McDowell
Use of Lipid-Lowering Agents, Indication Bias, and the Risk of Dementia in Community-Dwelling Elderly People
Arch Neurol,
February 1, 2002;
59(2):
223 - 227.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Reynish, S. Andrieu, F. Nourhashemi, and B. Vellas
Nutritional Factors and Alzheimer's Disease
J Gerontol A Biol Sci Med Sci,
November 1, 2001;
56(11):
M675 - M680.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. J. Launer, L. R. White, H. Petrovitch, G. W. Ross, and J. D. Curb
Cholesterol and neuropathologic markers of AD: A population-based autopsy study
Neurology,
October 23, 2001;
57(8):
1447 - 1452.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kalmijn, D. Foley, L. White, C. M. Burchfiel, J. D. Curb, H. Petrovitch, G. W. Ross, R. J. Havlik, and L. J. Launer
Metabolic Cardiovascular Syndrome and Risk of Dementia in Japanese-American Elderly Men : The Honolulu-Asia Aging Study
Arterioscler Thromb Vasc Biol,
October 1, 2000;
20(10):
2255 - 2260.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. Knittweis, W. A. McMullen, S. N. Romas, R. Mayeux, A. J. C. Slooter, A. Ruitenberg, C. M. van Duijn, M. M. B. Breteler, and H. C. Liu
The effect of apoE on dementia is not through atherosclerosis: The Rotterdam Study
Neurology,
June 27, 2000;
54(12):
2356 - 2358.
[Full Text]
[PDF]
|
|
|
|
